Kumar, MD, senior medical advisor at Cornell University and chief medical officer at Found
A long-acting release form of exenatide (exenatide ER, Bydureon) was approved by the FDA in 2012, becoming the first once-weekly injection of a GLP-1RA for adults with T2DM [ Table 2 ]
Current Phase 3 trials (expected to report results in 2027) are exploring doses ranging from 4mg to 12mg weekly, with some protocols testing up to 16mg
Well let the digital stacks of research below answer that for you: Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis Once-Weekly Semaglutide in Adults with Overweight or Obesity A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder Weight-Loss Drugs Like Ozempic Are Treating Binge Eating, Too Dulaglutide Reduces Binge Eating in Patients With T2D and Binge Eating Disorder Tirzepatide Once Weekly for the Treatment of Obesity Wegovy (semaglutide): a new weight loss drug for chronic weight management Liraglutide for psychiatric disorders: clinical evidence and challenges The use of GLP-1 agonists in the treatment of binge-eating disorder, emotional eating, overweight, and food noise offers much hope and promise to those who have struggled with these debilitating lifelong issues
It offers a chance to review appropriate options and build a structured weight-management plan with follow-up
The pricing between these two products is comparable, and both offer subscription discounts
